Proteins are foundational to therapeutic discovery and human health. The use of machine learning and artificial intelligence is set to revolutionize the development of protein biologics and tools for biotechnology processes. A unique high throughput chemistry combined with our software platform are now opening a new dimension for the industry.
At Avenue Biosciences, our team is dedicated to accelerating the discovery and development of protein biologics and tools for biotechnology industry, so that no lifesaving therapy goes unrealized because of production barriers.
Our transatlantic team is based in Helsinki, Finland, and Palo Alto, California.
MEET THE TEAM
An experienced life science entrepreneur, investor, advisor and board member based in San Francisco, CA, USA. Tero-Pekka Alastalo (MD, PhD) has 12+ years experience in life science startups and +10 years of clinical and translational research experience.
With 15+ years experience in protein production and commercial operations, Katja Rosti (PhD, eMBA) is the operational lead and co-inventor of Avenue Biosciences’ technology. During her international career, Katja Rosti has worked at Finnzymes, Thermo Fisher Scientific, Helsinki Institute of Life Science and the University of Helsinki.
As the inventor of Avenue Biosciences’ novel technology, Juho Kellosalo (PhD) leads the laboratory research and development efforts, leveraging 10+ years of experience in protein research and discovery from the University of Helsinki.
Juulia Simonen has 10+ years' experience in building brand awareness, PR and thought leadership for rapidly growing companies in life sciences, health technologies and finance.
Anton Klåvus has worked 5+ years building machine learning applications and all things data in life science startups, academia and larger companies. His work spans both development and customer-facing roles, bridging science and industry.
Ville Paavilainen is Research Director at the University of Helsinki with 20+ years of experience in protein science. Paavilainen is deeply involved in small molecule drug discovery and chemical probes projects. He is a co-founder of Avenue Biosciences and a co-inventor of their novel technology.
With an experience spanning over three decades, Gary Zweiger has held executive business development positions at Agilent, Affymetrix and ABI. He has a PhD in genetics from Stanford University, and serves as an advisor for private equity and angel investments.
A brand-building expert and executive with two decades of experience, helping life science startups bring their brands to life. Built successful brands as an executive at companies such as Blueprint Genetics.
Jens Vogel has a strong track record as senior executive at companies such as Bayer and Boehringer Ingelheim. He has deep expertise in development and manufacturing of diverse biotechnology portfolios (biologics, cell & gene therapy, mRNA), including for customers.
October 22, 2024
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering
October 7, 2024
Avenue Biosciences Welcomes Industry Experts to Advisory Board for Market Insights and Focused Growth
October 4, 2024
Avenue Biosciences Joins StartX, the Largest Community of Stanford Founders
